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Results of liver transplantation (LT) for hepatitis B have
improved significantly with the use of hepatitis B immune
globulin (HBIG) and/or lamivudine. The aim of this
study is to review the long-term outcome of patients who
underwent LT for hepatitis B. Records of 41 patients who
underwent LT for hepatitis B and survived 3 months or
longer post-LT were reviewed. Twenty patients were
administered no immunoprophylaxis or short-term intra-
muscular HBIG, whereas 21 patients were administered
high-dose intravenous (IV) HBIG. Median post-LT
follow-up in these 2 groups was 76 months (range, 4 to
155 months) and 25 months (range, 4 to 68 months),
respectively. Hepatitis B recurred in 15 (75%) and 4
patients (19%) who underwent LT in the pre-HBIG and
post-HBIG eras, respectively. Cumulative rates of recur-
rent hepatitis B at 1 and 3 years post-LT in these 2 groups
were 66% and 77% and 20% and 20%, respectively (P <
.001). Recurrent hepatitis B in the post-HBIG era corre-
lated with antibody to hepatitis B surface antigen titer less
than 100 IU/L. Nine patients with recurrent hepatitis B
were administered lamivudine for 13 to 49 months (medi-
an, 28 months); 6 patients continued to have stable or
improved liver disease, whereas 3 patients developed viro-
logical breakthrough with slow deterioration of liver dis-
ease. Long-term IV HBIG is effective in preventing recur-
rent hepatitis B. The risk for recurrent hepatitis B is
negligible after the first year post-LT. Among patients with
no virological breakthrough, lamivudine can stabilize or
improve liver disease for up to 4 years in patients with recur-
rent hepatitis B post-LT. (Liver Transpl 2001;7:724-731.)
Early results of liver transplantation (LT) for hepa-titis B were poor, with a recurrent hepatitis B rate
of 80% and 2-year mortality rate of 50%.1-3 Long-term
(6 months) immunoprophylaxis with high-dose
hepatitis B immune globulin (HBIG) has been effective
in reducing the rates of recurrent hepatitis B, as well as
graft and patient mortality, after LT.4-7 Nevertheless,
hepatitis B still recurs in some patients administered
long-term HBIG therapy. Recurrence may be second-
ary to a high viral load pre-LT or immune escape muta-
tions in the hepatitis B virus (HBV) S gene.8,9 Overall
recurrence rates with HBIG monotherapy vary from
15% to 50%, but may be as high as 80% in patients
who are hepatitis B e antigen (HBeAg) or HBV DNA
positive before LT.4,10-15 Pharmacokinetic studies
showed significant variability in antibody to hepatitis B
surface antigen (anti-HBs) titers post-LT, particularly
during the first 3 months.16 Until now, the efficacy of
HBIG beyond the first 2 to 3 years post-LT has not
been reported.
In the last few years, lamivudine has been shown to
be effective in decreasing recurrent hepatitis B post-
LT.17,18 However, the long-term efficacy of lamivudine
monotherapy may be limited by the selection of drug-
resistant mutants.19 Recent studies showed that the
combination of HBIG and lamivudine may be more
effective and may reduce recurrent hepatitis B to less
than 5%; however, the number of patients involved in
these studies is small, and the duration of post-LT fol-
low-up is limited.20-23
Lamivudine also has been shown to be effective in
the treatment of patients with recurrent hepatitis B
post-LT.24 However, breakthrough infection caused by
lamivudine-resistant mutants developed in 27% of
patients after 1 year of treatment. Thus, the long-term
benefits of lamivudine treatment in patients with recur-
rent hepatitis B post-LT remain to be determined.
The primary aim of this study is to review the long-
term outcome of patients who underwent LT for
hepatitis B. Secondary aims are to determine (1) the
efficacy of indefinite high-dose HBIG in the prevention
of recurrent hepatitis B, and (2) long-term safety and
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(Ann Arbor, MI). Fifty-nine patients (6.3%) underwent LT
for HBV-related acute or chronic liver failure. All patients had
detectable hepatitis B surface antigen (HBsAg) in serum at the
time of LT. Medical records of 41 patients who survived more
than 3 months post-LT were reviewed to assess hepatitis B
recurrence and outcome (Table 1). For each patient, baseline
demographic data, indications for LT, and results of sequen-
tial liver biochemistry tests, hepatitis B serological tests, and
HBV DNA tests, as well as the use of antiviral therapy pre-LT
and prophylactic immune/antiviral therapies post-LT, were
recorded.
Outcome
Primary outcomes of this study are patient survival and rate of
recurrent hepatitis B post-LT. Recurrent hepatitis B is defined
as the detection of HBsAg more than 1 month post-LT.
Breakthrough HBV infection during lamivudine therapy is
defined as the persistent reappearance of HBV DNA in serum
after its initial disappearance on at least 2 occasions, deter-
mined by non–polymerase chain reaction (PCR)-based
assays.
Prophylactic Therapy
Patients were divided into 2 groups based on the use of immu-
noprophylaxis post-LT. During the pre-HBIG era (before
January 1994), 20 patients were administered no or only
short-term (6 months) intramuscular HBIG (Abbott
Laboratories, Abbott Park, IL). In the post-HBIG era (after
January 1994), 21 patients were administered 10,000 IU of
intravenous (IV) HBIG during the anhepatic phase, daily for
the next 6 days, and monthly thereafter (Table 1). HBIG
protocols were approved by the University of Michigan Insti-
tution Review Board. Four patients in the post-HBIG era
were also administered lamivudine (100 mg/d) before LT
(median, 9.5 months; range, 1 to 17 months). These 4
patients were administered the same dose of HBIG as listed.
Three patients were HBeAg positive and had detectable HBV
DNA before lamivudine treatment. All 3 patients had unde-
tectable HBV DNA and cleared HBeAg before LT. No
patient developed lamivudine resistance before LT.
Monitoring Post-LT
During the pre-HBIG era, patients were followed up monthly
during the first year post-LT and every 3 to 6 months there-
after. During the post-HBIG era, patients were administered
monthly HBIG infusions and follow-up care at the Trans-
plant Ambulatory Care Unit. Hepatitis B serological assays
were performed every 3 to 6 months during the pre-HBIG
era. HBsAg and trough anti-HBs titers were checked before
each infusion, and serum HBV DNA was tested every 4
months in the post-HBIG era.
Hepatitis serological tests (HBsAg, HBeAg, anti-HBs,
antibody to HBeAg, antibody to hepatitis C virus, and anti-
body to hepatitis D virus [HDV]) were performed using
commercially available enzyme-linked immunoassays
(Abbott Laboratories). Serum HBV DNA was determined by
non–PCR-based assays, which included liquid hybridization
(Abbott) and branched DNA assays (Bayer Corp, Norwood,
MA). Serum anti-HBs titer was measured using an enzyme-
linked assay (AUSAB; Abbott). Lamivudine-resistant HBV P
gene mutations were examined by PCR and direct sequenc-
ing.25
Management of Patients With Recurrent
Hepatitis B Post-LT
Before the availability of lamivudine, patients with recurrent
hepatitis B did not undergo antiviral therapy. Re-LT was
performed in selected patients with recurrent liver failure.
After lamivudine became available in 1996, 9 patients with
recurrent hepatitis B were treated with lamivudine (100
mg/d). Of these, 7 patients underwent LT in the pre-HBIG,
and 2 patients, in the post-HBIG era. The latter 2 patients
had not been administered lamivudine previously.
Statistical Analyses
Data were entered into an Excel (Microsoft Corp, Redmond,
WA) database and analyzed using SPSS version 9.0 software
package (SPSS Inc, Chicago, IL.). Statistical analyses were
performed using Chi-squared and Fisher’s exact tests for
categorical variables. Paired and unpaired Student’s t-tests
were used for continuous variables. Time to recurrent hepa-
titis B was estimated using the Kaplan-Meier method and
compared using the log-rank test. Results are considered sta-
tistically significant at P  .05.
Results
Baseline characteristics of the patients are listed in Table
1. Sex, ethnicity, indications for LT, frequency of HDV
coinfection, HBeAg status at listing, and liver biochem-
istry test results at LT were similar between the 2
groups. However, patients who underwent LT in the
pre-HBIG era were significantly younger (P  .01).
Most patients who underwent LT in the post-HBIG
Table 1. Characteristics of Patients at Transplant Listing
Pre-HBIG
Era (n  20)
Post-HBIG
Era (n  21) P
Age (yr) 38  3 49  2 .01
Men/women 17/3 19/2 NS
White/black/Asian 18/2/0 20/1/0 NS
Cirrhosis/FHF/HCC 17/3/0 18/2/1 NS
1st/re-LT 19/1 17/4 NS
HCV coinfection 1/3 3/17 NS
HDV coinfection 0/12 2/10 NS
HBeAg 7/13 14/19 NS
HBV DNA NA 13/17
Abbreviations: NS, not significant; FHF, fulminant hepatic
failure; HCC, hepatocellular carcinoma; NA, not available.
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era had features that predicted high risks for recurrent
hepatitis B: 90% had cirrhosis, 74% were HBeAg pos-
itive, and 76% had detectable serum HBV DNA at
listing; only 20% had HDV coinfection.
Median duration of post-LT follow-up in the pre-
HBIG and post-HBIG eras was 76 months (range, 4 to
155 months) and 25 months (range, 4 to 68 months),
respectively.
Recurrent Hepatitis B
In the pre-HBIG era, 15 patients (75%) developed
recurrent hepatitis B: 13 patients experienced recur-
rence in the first year, and 2 patients, in the second year
post-LT. In the post-HBIG era, only 4 patients (19%)
developed recurrent hepatitis B, all 4 patients during
the first year post-LT. Cumulative rates of recurrent
hepatitis B after 1, 3, and 5 years post-LT were 66%,
77%, and 77% among patients who underwent LT in
the pre-HBIG era and 20%, 20%, and 20% among
patients who underwent LT in the post-HBIG era
(P  .001; Fig. 1). None of the 4 patients administered
combination prophylaxis of IV HBIG and lamivudine
developed recurrent hepatitis B after a median of
17 months (range, 9 to 25 months) of post-LT follow-
up. Thus, hepatitis B recurred in 4 of 17 patients (24%)
administered HBIG monotherapy.
Factors Associated With Recurrent Hepatitis B
in the Post-HBIG Era
Anti-HBs titer was the most important factor associated
with recurrent hepatitis B in the post-HBIG era. Of the
4 patients with recurrent hepatitis B, 2 patients missed
Figure 1. Kaplan-Meier curves
showing rates of recurrent hep-
atitis B post-LT in patients
who underwent LT in the pre-
HBIG and post-HBIG eras.




(n  21) P
Median duration of post-LT follow-up (mo) 76 25 .05
Recurrent hepatitis B 15 (75) 4 (19) .001
All-cause mortality 6 3 NS
Death related to recurrent hepatitis B 5 2 NS
No recurrent hepatitis B 5 (25) 17 (81) .001
All-cause mortality 3 3 NS
NOTE. Values expressed as number of patients (percent) unless stated otherwise.
Abbreviation: NS, not significant.
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1 dose of HBIG during the first 3 months post-LT and
hepatitis B recurred during months 4 and 6 post-LT.
The other 2 patients were not able to maintain an
anti-HBs titer greater than 100 IU/L after the first
4 months despite strict adherence to the HBIG proto-
col, and hepatitis B recurred during months 5 and 8
post-LT (Fig. 2A). In the remaining 17 patients with no
recurrence, lowest trough anti-HBs titers during
months 0 to 3, 4 to 6, and 7 to 12 post-LT were 217,
417, and 515 IU/L, respectively (Fig. 2B). Despite wide
variation in anti-HBs titers during the first year, a stable
anti-HBs titer greater than 500 IU/L was maintained in
all uninfected patients after the first year post-LT.
In the post-HBIG era, data on HBeAg and HBV
DNA at presentation were available for 19 patients.
None of the 6 patients who were HBeAg and HBV
DNA negative at presentation developed recurrent hep-
atitis B compared with 3 of 13 patients (23%) who were
HBeAg and/or HBV DNA positive at presentation.
HBeAg and HBV DNA results at presentation were not
available in the fourth patient who developed recurrent
hepatitis B.
Treatment and Outcome of Patients With
Recurrent Hepatitis B
Of the 15 patients who underwent LT in the pre-HBIG
era who developed recurrent hepatitis B, 6 patients died
4 to 30 months (median, 14 months) post-LT (Table
2). Five patients died of causes related to recurrent
hepatitis B: 3 patients of progressive liver failure 4, 9,
and 12 months after the diagnosis of recurrent hepatitis
B, and 2 patients of postoperative complications after
Figure 2. (A) Sequential anti-
HBs titer (log10 values, IU/L)
of the 4 patients who devel-
oped recurrent hepatitis B
despite IV HBIG.
Figure 2. (B) Sequential anti-
HBs titer (log10 values, IU/L)
during the first year post-LT
in the 17 patients adminis-
tered IV HBIG who did not
have recurrent hepatitis B.
Box plots indicate 75th per-
centile, median, and 25th
percentile values, the wickers
indicate the highest and low-
est values.
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re-LT for recurrent hepatitis B. The sixth patient died
of sepsis 26 months after the diagnosis of recurrent
hepatitis B with normal graft function at the time of
death. One patient was lost to follow-up 121 months
after LT; liver biochemistry test results were normal
during the last follow-up. Of the remaining 8 patients,
1 patient had normal graft function and undetectable
serum HBV DNA 129 months after the diagnosis of
recurrent hepatitis B. The other 7 patients were admin-
istered lamivudine treatment.
Of the 4 patients who underwent LT in the post-
HBIG era who developed recurrent hepatitis B, 1
patient died of progressive graft failure 9 months post-
LT, and 1 patient died of sepsis 2 months after re-LT
for recurrent hepatitis B. The other 2 patients were
administered lamivudine treatment.
Nine patients were administered lamivudine ther-
apy (Table 3). The median duration of treatment was
28 months (range, 13 to 49 months). Six patients had
histological cirrhosis before the onset of treatment. The
interval from diagnosis of recurrent hepatitis B to initi-
ation of lamivudine treatment varied from 2 to 131
months (median, 96 months). Eight patients were
HBeAg positive and 7 patients had detectable serum
HBV DNA before treatment. All patients had unde-
tectable serum HBV DNA and improvement in liver
biochemistry results within 6 months of treatment.
However, only 1 patient cleared HBeAg and no patient
cleared HBsAg. Three patients developed virological
breakthroughs after 11, 12, and 19 months of lamivu-
dine therapy. Two patients (no. 8 and 9) were con-
firmed to have mutations involving the YMDD motif
of the polymerase gene. All 3 patients had slow deteri-
oration in liver disease; 1 patient was started on adefovir
dipivoxil treatment (patient 9) and 1 patient was main-
tained on lamivudine therapy only because of noncom-
pliance and chronic renal insufficiency (patient 4),
whereas the third patient died of a cerebrovascular acci-
dent (patient 8). Six patients had persistently undetect-
able serum HBV DNA and continued improvement in
liver disease (Fig. 3) 13 to 49 months (median, 48
months) after the initiation of lamivudine treatment.
Discussion
In this study, we reported the outcome of patients with
hepatitis B up to 14 years post-LT. We found that
hepatitis B recurred in 75% of patients administered no
prophylaxis or short-term low-dose HBIG and 19% of
those administered long-term high-dose HBIG. These
data are similar to previously published reports4,10-16
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vention of recurrent hepatitis B post-LT. Of the 4
patients who underwent LT in the post-HBIG era and
developed recurrent hepatitis B, 3 of 3 patients tested
were HBeAg positive and had detectable HBV DNA
pre-LT. Two patients missed 1 dose of HBIG during
the first 3 months post-LT, and 2 patients were unable
to maintain anti-HBs titers greater than 100 IU/L
despite strict adherence to a fixed-dose protocol. These
data support the observations that (1) patients with a
high viral load pre-LT have an increased risk for recur-
rent hepatitis B post-LT, (2) a fixed-dose regimen of
HBIG administration may be insufficient in maintain-
ing protective levels of anti-HBs in patients who are
HBeAg and/or HBV DNA positive pre-LT, and (3)
adequate anti-HBs titers must be maintained to prevent
recurrent hepatitis B.4,15,16 Our data suggest that close
monitoring of anti-HBs titer with supplemental HBIG
when titers decrease to less than a protective level or
more aggressive prophylactic regimen is needed for
patients with a high viral load pre-LT. In accordance
with other reports,20-23 none of our 4 patients adminis-
tered combination prophylaxis with HBIG and lamivu-
dine developed recurrent hepatitis B after a median
follow-up of 17 months.
We found most (89%) hepatitis B recurrence during
the first year post-LT, and all recurrence within the first
2 years. These data suggest that despite the persistence
of HBV DNA in the liver or extrahepatic reservoirs,14,26
neutralization of circulating virions and prevention of
early graft infection when patients are heavily immuno-
suppressed may be the most important steps in the
prevention of recurrent hepatitis B post-LT. Two of our
patients who underwent LT in the pre-HBIG era had
no evidence of reinfection up to 10 years after LT. Our
findings suggest that prophylactic regimens may be
tapered after the first 1 to 2 years post-LT because the
risk for recurrent hepatitis B decreases. We are currently
evaluating a tapering regimen in patients who have no
evidence of recurrent hepatitis B after 1 year post-LT.
As in other studies,1,27 we found that patients with
recurrent hepatitis B post-LT had rapidly progressive
liver disease; 37% developed graft failure within 1 year,
Figure 3. Serial values (me-
dian) of serum albumin, ala-
nine aminotransferase, and
total bilirubin in 9 patients
administered lamivudine for
recurrent hepatitis B. Bio-
chemical values from the time
recurrent hepatitis B was
diagnosed were plotted to
show changes before and after
lamivudine treatment. (BK,
virological breakthrough.)
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and 78% of deaths were related to recurrent hepatitis B.
The dismal outcome of patients with recurrent hepatitis
B improved after lamivudine became available. Of the
9 patients administered lamivudine treatment, none
died of graft failure after a median treatment duration
of 28 months, although 6 patients had cirrhosis and
4 patients had mild hepatic decompensation when
treatment was initiated. In accordance with other
reports,24,28,29 all our patients had virological response,
as well as clinical and biochemical improvement
initially. Six patients with no breakthrough infection
continued to have improved or stable liver disease up to
4 years after the initiation of lamivudine treatment. Of
the 3 patients who developed virological break-
throughs, all had slow deterioration in liver disease.
However, comorbid medical conditions and the addi-
tion of adefovir dipivoxil preclude us from determining
the long-term effects of lamivudine-resistant HBV
mutants in these patients.
In summary, our study showed that long-term high-
dose IV HBIG is effective in preventing recurrent hep-
atitis B post-LT, especially in patients with a low viral
load pre-LT or when anti-HBs titer was maintained at
greater than 100 IU/L. We found that the risk for
recurrent hepatitis B was very low after the first year
post-LT. These data indicate that aggressive prophy-
laxis is needed during the initial post-LT period, espe-
cially in patients with a high viral load pre-LT, but the
prophylactic regimen can be tapered with time. Our
data showed that in patients with recurrent hepatitis B,
lamivudine is effective in stabilizing or improving liver
disease for up to 4 years, but the clinical benefits may be
negated in patients with virological breakthrough infec-
tion.
References
1. Demetris AJ, Todo S, Van Thiel DH, Fung JJ, Iwaki Y, Sysyn G,
et al. Evolution of hepatitis B virus liver disease after hepatic
replacement. Practical and theoretical considerations. Am J
Pathol 1990;137:667-676.
2. O’Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson
PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic
liver transplantation. Serological and clinical implications.
J Hepatol 1992;14:104-111.
3. Eason JD, Freeman RB Jr, Rohrer RJ, Lewis WD, Jenkins R,
Dienstag J, et al. Should liver transplantation be performed for
patients with hepatitis B? Transplantation 1994;57:1588-1593.
4. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Ben-
hamou JP, et al. Liver transplantation in European patients with
the hepatitis B surface antigen. N Engl J Med 1993;329:1842-
1847.
5. Lawchart W, Muller R, Pichlmayr R. Long-term immunopro-
phylaxis of hepatitis B reinfection in recipients of human liver
allografts. Transplant Proc 1987;19:4051-4053.
6. Perrillo RP, Mason AL. Hepatitis B and liver transplantation.
Problems and promises. N Engl J Med 1993;329:1885-1887.
7. Muller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H,
Alexander GJ. “EUROHEP” consensus report on the manage-
ment of liver transplantation for hepatitis B virus infection.
European Concerted Action on Viral Hepatitis. J Hepatol 1994;
21:1140-1143.
8. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling
JM, et al. Hepatitis B virus S mutants in liver transplant recipi-
ents who were reinfected despite hepatitis B immune globulin
prophylaxis. Hepatology 1998;27:213-222.
9. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf
U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with
antigenically altered hepatitis B surface antigen is selected by
high-dose hepatitis B immune globulin after liver transplanta-
tion. Hepatology 1998;27:254-263.
10. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M,
Benhamou JP, et al. Passive immunoprophylaxis after liver trans-
plantation in HBsAg-positive patients. Lancet 1991;337:813-
815.
11. Lemmens HP, Langrehr JM, Blumhardt G, Lohmann R, Knoop
M, Verschl J, et al. Outcome following orthotopic liver trans-
plantation in HBsAg-positive patients using short- or long-term
immunoprophylaxis. Transplant Proc 1994;26:3622-3623.
12. Langrehr JM, Lemmens HP, Keck H, Lohmann R, Knoop M,
Neumann U, et al. Liver transplantation in hepatitis B surface
antigen positive patients with postoperative long-term immuno-
prophylaxis. Transplant Proc 1995;27:1215-1216.
13. Grazi GL, Mazziotti A, Sama C, Jovine E, Stefanini F, Paladini
R, et al. Liver transplantation in HBsAg-positive HBV-DNA-
negative cirrhotics: Immunoprophylaxis and long-term out-
come. Liver Transpl Surg 1996;2:418-425.
14. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP,
et al. Prophylaxis in liver transplant recipients using a fixed dos-
ing schedule of hepatitis B immunoglobulin. Hepatology 1996;
24:1327-1333.
15. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC,
McCullough CS, Dickson RC, et al. Improved outcome of
orthotopic liver transplantation for chronic hepatitis B cirrhosis
using aggressive passive immunization. Transplantation 1996;
61:1358-1364.
16. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shep-
hard BL, Houlgrave CW, et al. Improved clinical outcome with
liver transplantation for hepatitis B-induced chronic liver failure
using passive immunization. Ann Surg 1998;227:841-850.
17. Grellier L, Multimer D, Ahmed M, Brown D, Burroughs AK,
Rolles K, et al. Lamivudine prophylaxis against reinfection in
liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:
1212-1215.
18. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al.
A multi-center United States-Canadian trial to assess lamivudine
monotherapy before and after liver transplantation for chronic
hepatitis B. Hepatology 2001;33:424-432.
19. Mutimer DJ, Pillay D, Dragon E, Tang H, Ahmed M,
O’Donnell K, et al. High pre-treatment serum hepatitis B virus
titre predicts failure of lamivudine prophylaxis and graft re-in-
fection after liver transplantation. J Hepatol 1999;30:715-721.
20. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P,
Yersiz H, et al. Prophylaxis against hepatitis B recurrence follow-
ing liver transplantation using combination lamivudine and hep-
atitis B immune globulin. Hepatology 1998;28:585-589.
730 Chu et al
21. Yao YF, Osorio RW, Roberts JP, Poordad FF, Briceno MN,
Garcia-Kennedy R, et al. Intramuscular hepatitis B immune
globulin combined with lamivudine for prophylaxis against hep-
atitis B recurrence after liver transplantation. Liver Transpl Surg
1999;5:491-496.
22. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW,
Frighetto L, et al. Liver transplantation for chronic hepatitis B
infection with the use of combination lamivudine and low-dose
hepatitis B immune globulin. Liver Transpl Surg 1999;5:520-
525.
23. Angus PW, McCaughan GW, Gane EJ, Crawford DHG, Harley
H, Australasian Liver Transplant Study Group. Combination
low-dose hepatitis B immune globulin and lamivudine therapy
provides effective prophylaxis against post-transplantation hep-
atitis B. Liver Transpl 2000;6:429-433.
24. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et
al. Multicenter study of lamivudine therapy for hepatitis B after
liver transplantation. Hepatology 1999;29:1581-1586.
25. Lok ASF, Hussain M, Cursano C, Margotti M, Gramenzi A,
Grazi GL, et al. Evolution of hepatitis B virus polymerase gene
mutations in hepatitis B e antigen negative patients receiving
lamivudine therapy. Hepatology 2000;32:1145-1153.
26. Feray C, Zignego AL, Samuel D, Bismuth A, Reynes M, Tiollais
P, et al. Persistent hepatitis B virus infection of mononuclear
blood cells without concomitant liver infection. The liver trans-
plantation model. Transplantation 1990;49:1155-1158.
27. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl
TE. Orthotopic liver transplantation for patients with hepatitis B
virus related liver disease. Hepatology 1991;13:619-626.
28. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis
AG. Efficacy of lamivudine in controlling hepatitis B virus recur-
rence after liver transplantation. Transplantation 1998;65:1615-
1621.
29. Malkan G, Cattral MS, Humar A, Asghar HA, Greig PD, Hem-
ming AW, et al. Lamivudine for hepatitis B in liver transplanta-
tion. Transplantation 2000;69:1403-1407.
731Liver Transplantation for Hepatitis B
